Predicting Unplanned Hospital Readmissions in Patients With Hematologic Malignancies

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.